PHARMACOTHERAPY GLP-1 analogues and insulin: sound the wedding bells?

被引：30

作者：

Nauck, Michael A. ^{[1
]}

Meier, Juris J. ^{[2
]}

机构：

[1] Diabet Zentrum Bad Lauterberg, D-37431 Bad Lauterberg Im Harz, Germany

[2] Klinikum Ruhr Univ Bochum, St Josef Hosp, Dept Internal Med 1, D-44791 Bochum, Germany

来源：

NATURE REVIEWS ENDOCRINOLOGY | 2011年 / 7卷 / 04期

关键词：

TYPE-2; EXENATIDE; GLUCOSE; GLARGINE; EFFICACY; THERAPY;

D O I：

10.1038/nrendo.2011.30

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A large-scale, placebo-controlled clinical study shows a remarkable benefit from adding exenatide, a short-acting GLP-1receptor agonist, to insulin glargine, on a background of metformin and/or pioglitazone, in patients with type 2 diabetes mellitus. Is this partnership here to stay?

引用

页码：193 / 195

页数：2

共 10 条

[1] Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin A proof-of-concept study [J].

Arnolds, Sabine ;

Dellweg, Sibylle ;

Clair, Janina ;

Dain, Marie-Paule ;

Nauck, Michael A. ;

Rave, Klaus ;

Kapitza, Christoph .

DIABETES CARE, 2010, 33 (07) :1509-1515

[2] Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes A Randomized, Controlled Trial [J].

Buse, John B. ;

Bergenstal, Richard M. ;

Glass, Leonard C. ;

Heilmann, Cory R. ;

Lewis, Michelle S. ;

Kwan, Anita Y. M. ;

Hoogwerf, Byron J. ;

Rosenstock, Julio .

ANNALS OF INTERNAL MEDICINE, 2011, 154 (02) :103-+

[3] Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J].

Buse, John B. ;

Rosenstock, Julio ;

Sesti, Giorgio ;

Schmidt, Wolfgang E. ;

Montanya, Eduard ;

Brett, Jason H. ;

Zychma, Marcin ;

Blonde, Lawrence .

LANCET, 2009, 374 (9683) :39-47

[4] SAFETY AND EFFICACY OF NORMALIZING FASTING GLUCOSE WITH BEDTIME NPH INSULIN ALONE IN NIDDM [J].

CUSI, K ;

CUNNINGHAM, GR ;

COMSTOCK, JP .

DIABETES CARE, 1995, 18 (06) :843-851

[5] The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [J].

Drucker, Daniel J. ;

Nauck, Michael A. .

LANCET, 2006, 368 (9548) :1696-1705

[6] Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes [J].

Holman, Rury R. ;

Farmer, Andrew J. ;

Davies, Melanie J. ;

Levy, Jonathan C. ;

Darbyshire, Julie L. ;

Keenan, Joanne F. ;

Paul, Sanjoy K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (18) :1736-1747

[7] Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine Hagedorn insulin in patients with type 2 diabetes [J].

Linn, Thomas ;

Fischer, Britta ;

Soydan, Nedim ;

Eckhard, Michael ;

Ehl, Julia ;

Kunz, Clemens ;

Bretzel, Reinhard G. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (10) :3839-3846

[8] Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes [J].

Linnebjerg, Helle ;

Park, Soomin ;

Kothare, Prajakti A. ;

Trautmann, Michael E. ;

Mace, Kenneth ;

Fineman, Mark ;

Wilding, Ian ;

Nauck, Michael ;

Horowitz, Michael .

REGULATORY PEPTIDES, 2008, 151 (1-3) :123-129

[9] Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes [J].

Nathan, D. M. ;

Buse, J. B. ;

Davidson, M. B. ;

Ferrannini, E. ;

Holman, R. R. ;

Sherwin, R. ;

Zinman, B. .

DIABETOLOGIA, 2009, 52 (01) :17-30

[10] Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial [J].

Russell-Jones, D. ;

Vaag, A. ;

Schmitz, O. ;

Sethi, B. K. ;

Lalic, N. ;

Antic, S. ;

Zdravkovic, M. ;

Ravn, G. M. ;

Simo, R. .

DIABETOLOGIA, 2009, 52 (10) :2046-2055

← 1 →